Analyst firms · Morgan Stanley · CTKB

Morgan Stanley CTKB price target and rating history

Cytek Biosciences Inc. (CTKB) · Industrials

Morgan Stanley rates Cytek Biosciences Inc. (CTKB) Equal-Weight with a $6 price target, as of its latest action on Dec 2, 2025. It has published 4 rating actions on CTKB since August 2021, including 0 upgrades and 0 downgrades.

Current rating

Equal-Weight

Price target

$6

Median target, all firms

Too few

Actions on CTKB

4

Morgan Stanley price target on CTKB

Every Morgan Stanley rating on CTKB

• Dec 2, 2025
  ResumeMorgan Stanley resumes coverage at Equal-Weight, price target $6
• Feb 15, 2022
  ReiterateMorgan Stanley cuts its price target to $18 from $27, keeps Equal-Weight
• Aug 17, 2021
  InitiateMorgan Stanley starts coverage at Equal-Weight
• Aug 17, 2021
  InitiateMorgan Stanley starts coverage at Equal-Weight, price target $26

Questions about Morgan Stanley and CTKB

What is Morgan Stanley's price target for CTKB?

Morgan Stanley's latest stated price target for Cytek Biosciences Inc. (CTKB) is $6, from its action on Dec 2, 2025.

What is Morgan Stanley's rating on CTKB?

Morgan Stanley rates CTKB Equal-Weight, a neutral rating, as of Dec 2, 2025.

When did Morgan Stanley last change its view on CTKB?

On Dec 2, 2025, Morgan Stanley resumes coverage at Equal-Weight, price target $6.

More CTKB rating histories

• TD Cowen3

All Morgan Stanley ratingsCTKB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.